{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:36:11Z","timestamp":1791988571414,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1038\/bjc.2012.468","type":"journal-article","created":{"date-parts":[[2012,11,20]],"date-time":"2012-11-20T23:54:43Z","timestamp":1353455683000},"page":"1869-1875","source":"Crossref","is-referenced-by-count":159,"title":["VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2"],"prefix":"10.1038","volume":"107","author":[{"given":"N G","family":"Gavalas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Tsiatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Tsitsilonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Politi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A C","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rodolakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Thomakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Haidopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Antsaklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,20]]},"reference":[{"key":"BFbjc2012468_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ygyno.2007.10.018","volume":"108","author":"A Bamias","year":"2008","unstructured":"Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Papatheodoridis G, Archimandritis A, Antsaklis A, Dimopoulos MA (2008) Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 108: 421\u2013427","journal-title":"Gynecol Oncol"},{"key":"BFbjc2012468_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ygyno.2007.02.029","volume":"106","author":"A Bamias","year":"2007","unstructured":"Bamias A, Tsiatas ML, Kafantari E, Liakou C, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Tsitsilonis O, Bamia C, Papatheodoridis G, Politi E, Archimandritis A, Antsaklis A, Dimopoulos MA (2007) Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol 106: 75\u201381","journal-title":"Gynecol Oncol"},{"key":"BFbjc2012468_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4049\/jimmunol.0900397","volume":"184","author":"A Basu","year":"2010","unstructured":"Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, Calzadilla K, Pal S, Briscoe DM (2010) Cutting edge: vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol 184: 545\u2013549","journal-title":"J Immunol"},{"key":"BFbjc2012468_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc1093","volume":"3","author":"G Bergers","year":"2003","unstructured":"Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401\u2013410","journal-title":"Nat Rev Cancer"},{"issue":"Suppl_LBA1","key":"BFbjc2012468_CR5","first-page":"18s","volume":"28","author":"RA Burger","year":"2010","unstructured":"Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, Monk BJ, Greer BE, Boente M, Liang SX (2010) Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 28 (Suppl_LBA1): 18s","journal-title":"J Clin Oncol"},{"key":"BFbjc2012468_CR6","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.4049\/jimmunol.146.12.4414","volume":"146","author":"KD Crossland","year":"1991","unstructured":"Crossland KD, Lee VK, Chen W, Riddel SR, Greenberg PD, Cheever MA (1991) T cells from tumor immune mice nonspecifically expanded in vitro with anti CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 146: 4414\u20134420","journal-title":"J Immunol"},{"key":"BFbjc2012468_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581\u2013611","journal-title":"Endocr Rev"},{"key":"BFbjc2012468_CR8","first-page":"4140","volume":"55","author":"MR Freeman","year":"1995","unstructured":"Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, Peoples GE, Klagsbrun M (1995) Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55: 4140\u20134415","journal-title":"Cancer Res"},{"key":"BFbjc2012468_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2: 1096\u20131103","journal-title":"Nat Med"},{"key":"BFbjc2012468_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/ncponc0342","volume":"2","author":"G Gasparini","year":"2005","unstructured":"Gasparini G, Longo R, Toi M, Ferrara N (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2: 562\u2013577","journal-title":"Nat Clin Pract Oncol"},{"key":"BFbjc2012468_CR11","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1111\/j.1582-4934.2009.00695.x","volume":"13","author":"S Georgaki","year":"2009","unstructured":"Georgaki S, Skopeliti M, Tsiatas M, Nicolaou KA, Ioannou K, Husband A, Bamias A, Dimopoulos MA, Constantinou AI, Tsitsilonis OE (2009) Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. J Cell Mol Med 13: 3929\u20133938","journal-title":"J Cell Mol Med"},{"key":"BFbjc2012468_CR12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011\u20131027","journal-title":"J Clin Oncol"},{"key":"BFbjc2012468_CR13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1189\/jlb.71.6.907","volume":"71","author":"FH Igney","year":"2002","unstructured":"Igney FH, Krammer PH (2002) Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leucoc Biol 71: 907\u2013920","journal-title":"J Leucoc Biol"},{"key":"BFbjc2012468_CR14","first-page":"4257","volume":"51","author":"CG Ioannides","year":"1991","unstructured":"Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS (1991) Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51: 4257\u20134265","journal-title":"Cancer Res"},{"key":"BFbjc2012468_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jss.2008.12.014","volume":"159","author":"JM Lyons","year":"2010","unstructured":"Lyons JM, Schwimer JE, Anthony CT, Thomson JL, Cundiff JD, Casey DT, Maccini C, Kucera P, Wang YZ, Boudreaux JP, Woltering EA (2010) The role of VEGF pathways in human physiologic and pathologic angiogenesis. J Surg Res 159: 517\u2013527","journal-title":"J Surg Res"},{"key":"BFbjc2012468_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ygyno.2011.07.007","volume":"124","author":"M Markman","year":"2012","unstructured":"Markman M (2012) Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gyneacol Oncol 124: 171","journal-title":"Gyneacol Oncol"},{"key":"BFbjc2012468_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3109\/08977190903210863","volume":"27","author":"M Mikko","year":"2009","unstructured":"Mikko M, Wahlstr\u00f6m J, Grunewald J, Magnus Sk\u00f6ld C (2009) Hypoxia but not cigarette smoke modulates VEGF secretion from human T cells. Growth Factors 27: 352\u2013361","journal-title":"Growth Factors"},{"key":"BFbjc2012468_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00262-006-0234-7","volume":"56","author":"K Mimura","year":"2007","unstructured":"Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H (2007) Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 56: 761\u2013770","journal-title":"Cancer Immunol Immunother"},{"key":"BFbjc2012468_CR19","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.4049\/jimmunol.172.7.4618","volume":"172","author":"F Mor","year":"2004","unstructured":"Mor F, Quintana FJ, Cohen IR (2004) Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 172: 4618\u20134623","journal-title":"J Immunol"},{"key":"BFbjc2012468_CR20","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","volume":"101","author":"JE Ohm","year":"2003","unstructured":"Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP (2003) Vegf inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101: 4878\u20134886","journal-title":"Blood"},{"key":"BFbjc2012468_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12263-008-0076-3","volume":"3","author":"D Ribatti","year":"2008","unstructured":"Ribatti D, Vacca A (2008) The role of microenvironment in tumor angiogenesis. Genes Nutr 3: 29\u201334","journal-title":"Genes Nutr"},{"key":"BFbjc2012468_CR22","first-page":"2324","volume-title":"Molecular Cloning: A Laboratory Manual","author":"J Sambrook","year":"1989","unstructured":"Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning: A Laboratory Manual 2nd edn, pp 2324\u20132316. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY"},{"key":"BFbjc2012468_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cellimm.2009.01.006","volume":"256","author":"JY Shin","year":"2009","unstructured":"Shin JY, Yoon IH, Kim JS, Kim B, Park CG (2009) Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. Cell Immunol 256: 72\u201378","journal-title":"Cell Immunol"},{"key":"BFbjc2012468_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/eji.200939887","volume":"40","author":"H Suzuki","year":"2010","unstructured":"Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K, Morisaki T, Katano M (2010) VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol 40: 197\u2013203","journal-title":"Eur J Immunol"},{"key":"BFbjc2012468_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm1428","volume":"12","author":"BY Tam","year":"2006","unstructured":"Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, Jiang S, Nayak NR, Kuypers FA, Ma L, Sundram U, Wu G, Garcia JA, Schrier SL, Maher JJ, Johnson RS, Yancopoulos GD, Mulligan RC, Kuo CJ (2006) VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12: 793\u2013800","journal-title":"Nat Med"},{"key":"BFbjc2012468_CR26","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1084\/jem.20100438","volume":"207","author":"MJ Waldner","year":"2010","unstructured":"Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, Becker C, Weigmann B, Vieth M, Rose-John S, Neurath MF (2010) VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 207: 2855\u20132868","journal-title":"J Exp Med"},{"key":"BFbjc2012468_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1126\/science.1190310","volume":"328","author":"CL Zindl","year":"2010","unstructured":"Zindl CL, Chaplin DD (2010) Immunology. Tumor immune evasion. Science 328: 697\u2013698","journal-title":"Science"},{"key":"BFbjc2012468_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ijc.26094","volume":"130","author":"AC Ziogas","year":"2012","unstructured":"Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Antsaklis A, Dimopoulos MA, Bamias A (2012) VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int J Cancer 130: 857\u2013864","journal-title":"Int J Cancer"},{"key":"BFbjc2012468_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"W Zou","year":"2005","unstructured":"Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263\u2013274","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2012468_CR30","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A","volume":"75","author":"S Zucker","year":"1998","unstructured":"Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J (1998) Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 75: 780\u2013786","journal-title":"Int J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2012468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012468","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T15:45:19Z","timestamp":1714578319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2012468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["BFbjc2012468"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2012.468","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}